Okamoto, Yuko

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy Department of Pharmacy Social Pharmacy ( Shiba-Kyoritsu )

Position

Research Associate/Assistant Professor/Instructor

Career 【 Display / hide 】

  • 2018.04
    -
    2018.09

    株式会社 SKY CREATE 海浜総合薬局　薬剤師

  • 2018.10
    -
    2019.11

    シドニー大学薬学部 訪問研究員

  • 2019.12
    -
    2021.12

    アドバンス株式会社　さくら調剤薬局　薬剤師

  • 2021.12
    -
    2024.04

    株式会社 SKY CREATE 海浜総合薬局　管理薬剤師

  • 2024.05
    -
    2025.12

    慶應義塾大学薬学部　実務実習事前学習（実習）補助

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 2008.04
    -
    2014.03

    Sojo University

    University, Graduated

  • 2014.04
    -
    2018.03

    Sojo University

    Graduate School, Completed, Doctoral course

Page Top ▲
 

Papers 【 Display / hide 】

  • Application of epithelial lining fluid drug concentrations to MICi-Based PK/PD modeling of cefepime/nacubactam in a murine model of CPE pneumonia

    Mizukami Y., Takahashi M., Suzuki K., Duan S., Ikegami S., Muraishi T., Satake N., Okamoto Y., Igarashi Y., Enoki Y., Taguchi K., Matsumoto K.

    Journal of Infection and Chemotherapy 32 ( 1 ) 102889 2026.01

    ISSN  1341321X

    　View Summary

    Introduction: Nacubactam is a novel β-lactamase inhibitor with intrinsic antibacterial activity that shows therapeutic potential against carbapenemase-producing Enterobacterales when administered with β-lactam antibiotics. Pharmacokinetics/pharmacodynamics (PK/PD) analyses based on drug concentrations at the site of infection are recommended to better evaluate antibiotic efficacy. A new PD index, the instantaneous minimum inhibitory concentration (MIC<inf>i</inf>), which dynamically reflects the changing susceptibility of β-lactams during co-administration with β-lactamase inhibitors, has recently been proposed. This study aimed to assess the efficacy of cefepime combined with nacubactam in a murine model of pneumonia using MIC<inf>i</inf>-based PK/PD analysis in the lung epithelial lining fluid (ELF). Methods: In vitro pharmacodynamic testing using the checkerboard method was conducted with two β-lactamase-producing Klebsiella pneumoniae strains. In vivo PK and PD studies were performed in neutropenic mice using both β-lactamase-producing and non-producing strains. Drug concentrations in plasma and ELF were measured, and MIC<inf>i</inf>-based PK/PD analysis was conducted. Results: In vitro, the MIC of cefepime decreased in a concentration-dependent manner with increasing nacubactam. In the murine model of pneumonia, cefepime monotherapy resulted in bacterial changes of 0.12–4.30 log<inf>10</inf> CFU/lung, while the combination therapy reduced bacterial counts by −5.93 to −0.234 log<inf>10</inf> CFU/lung. The percentage of time that free cefepime concentrations exceeded MIC<inf>i</inf> (T > MIC<inf>i</inf>) was highly correlated with bacterial reduction. The target T > MIC<inf>i</inf> for maximal effect was estimated to be 29.3 %. Conclusions: These findings support the utility of MIC<inf>i</inf>-based PK/PD analysis for optimizing combination antibiotic therapy in pneumonia.

  • Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

    Kawasaki A., Shintani R., Takao R., Nakazawa Y., Mihara T., Ikegami S., Shimada S., Matsumoto Y., Okamoto Y., Igarashi Y., Enoki Y., Taguchi K., Matsumoto K.

    Medical Mycology 63 ( 10 )  2025.10

    ISSN  13693786

    　View Summary

    Background Isavuconazole (ISA) is a treatment option for invasive fungal infections (IFIs) and is known for a favorable safety profile compared with other antifungal agents. However, comprehensive evidence regarding its efficacy and safety remains limited. Objectives This study aimed to assess the efficacy and safety of ISA compared with other antifungal agents through a systematic review and meta-analysis restricted to randomized controlled trials (RCTs), to provide more reliable estimates of its clinical effects. Methods Following Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines, a comprehensive literature search was conducted using PubMed, the Cochrane Library, Web of Science, and ClinicalTrials.gov to identify RCTs comparing ISA with other antifungal agents. The primary outcomes were clinical response and mortality. Secondary outcomes included the incidence of adverse events, including serious, drug-related, and organ-specific toxicities. A subgroup analysis was conducted focusing on filamentous fungal infections, comparing ISA and voriconazole. Results Three RCTs met the inclusion criteria. No statistically significant differences were observed between ISA and comparator agents in terms of clinical response, mortality, or total and organ-specific adverse events. A trend toward fewer adverse events was noted in the ISA group. In the subgroup analysis, ISA and voriconazole showed similar efficacy and overall safety; however, the incidence of both drug-related adverse events and hepatobiliary disorders was significantly lower in the ISA group. Conclusions ISA demonstrated efficacy comparable to that of other antifungal agents, with a favorable safety profile in patients with IFIs, including filamentous fungal infections. This meta-analysis of RCTs provides high-quality evidence to support antifungal drug selection in clinical practice.

  • Analysis of Drug-Induced Xerostomia using the Japanese Adverse Drug Event Report Database.

    Shingo Kondo, Mari Maese, Nozomi Ito, Yuko Okamoto, Hiroki Iwata, Noriko Kobayashi, Katsunori Yamaura

    BPB Reports  2025.10

    Accepted

  • 医療用一般用共用医薬品 (仮称) の創設提言に対する薬剤師の認知および見解に関する実態把握調査.

    (医療薬学)  51 ( 4 ) 196 - 202 2025.04

    Research paper (scientific journal), Lead author, Accepted

  • Direct comparison of the effects of first- and second-generation H(1) -receptor blockers on motor functions in mice.

    Taguchi K, Tenjin K, Sakamoto Y, Shimada A, Hara R, Iketani O, Okamoto Y, Enoki Y, Kizu J, Hori S, Matsumoto K

    Die Pharmazie 80 ( 1 ) 24 - 28 2025.03

    Lead author,  ISSN  0031-7144

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • When Albumin Meets Liposomes: A Feasible Drug Carrier for Biomedical Applications

    Kazuaki Taguchi, Yuko Okamoto, Kazuaki Matsumoto, Masaki Otagiri, Victor Tuan Giam Chuang

    Pharmaceuticals  2021.03

  • Topical application of bacteriophages for treatment of wound infections

    Rachel Yoon Kyung Chang, Sandra Morales, Yuko Okamoto, Hak-Kim Chan

    Translational Research  2020.03

Page Top ▲

Presentations 【 Display / hide 】

  • パクリタキセル-アルブミン内包リポソームの作製と有用性評価

    岡本侑子、田口和明、櫻木美菜、山﨑啓之、小田切優樹

    [Domestic presentation]  第33回日本DDS学会学術集会, 

    2017.07
    , 

    Oral presentation (general)

  • Preparation of albumin-encapsulated liposome as a novel DDS carrier

    Yuko okamoto, Kazuaki Taguchi, Keishi Yamasaki, Mina Sakuragi, Shun’ichi Kuroda, Masaki otagiri

    [International presentation]  FIP Pharmaceutical Sciences World Congress 2017 (Stockholm) , 

    2017.05
    , 

    Poster presentation

  • アルブミン内包リポソームの新規難水溶性薬物キャリアとしての安全性評価

    岡本侑子、田口和明、山﨑啓之、櫻木美菜、黒田俊一、小田切優樹

    [Domestic presentation]  日本薬学会第137年会, 

    2017.03
    , 

    Oral presentation (general)

  • アルブミンとリポソームを融合した新規DDSキャリアの調製と評価

    岡本侑子、田口和明、山﨑啓之、櫻木美菜、黒田俊一、小田切優樹

    [Domestic presentation]  第32回日本DDS学会学術集会, 

    2016.07
    , 

    Oral presentation (general)

  • アルブミンとリポソームを融合した新規DDSキャリアの創製

    岡本侑子、山﨑啓之、榎田泰介、前田崇宏、田口和明、瀬尾量、小田切優樹

    [Domestic presentation]  日本薬学会第136年会, 

    2016.03
    , 

    Oral presentation (general)

display all >>

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • 日本医療薬学会, 

    2025.05
    -
    Present

  • 日本口腔ケア学会, 

    2025.03
    -
    Present

  • 日本老年薬学会, 

    2025.03
    -
    Present
Page Top ▲